
5.75.014

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Neuromuscular Agents	Original Policy Date:	October 7, 2016
Subject:	Exondys 51	Page:	1 of 6

Last Review Date: March 8, 2024

Exondys 51

Description

Exondys 51 (eteplirsen)

Background

Exondys 51 (eteplirsen) is indicated for patients with a diagnosis of Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. DMD is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by an exon mutation in a gene that codes for dystrophin, a protein that helps keep muscle intact. Exons are the sections of DNA that contain instructions for creating proteins; if an exon is mutated, a functional protein cannot be produced. Exondys 51 is designed to “skip over” a mutated exon and enable the synthesis of a shortened, functional form of dystrophin protein. Patients with DMD experience progressive loss of ambulation, followed by a need for assisted ventilation, and eventual death in mid-20s (1-2).

Regulatory Status

FDA-approved indication: Exondys 51 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping (1).

Exondys 51 clinical trials used a double-blind, placebo-controlled protocol to examine eteplirsen's ability to induce dystrophin production and improve distance walked on the 6-minute walk test (6MWT). Boys with DMD aged 7 to 13 years, with confirmed deletions correctable by skipping exon 51 and ability to walk 200 to 400 m on 6 MWT (2).

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Neuromuscular Agents	Original Policy Date:	October 7, 2016
Subject:	Exondys 51	Page:	2 of 6

Dystrophin levels should be measured at baseline to evaluate pretreatment dystrophin-positive fibers and sometime during therapy to evaluate the effect of Exondys 51 dose (2).

Related policies

Amondys 45, Elevidys, Emflaza, Viltepso, Vyondys 53

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Exondys 51 may be considered **medically necessary** if the conditions indicated below are met.

Exondys 51 may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 20 years of age or younger

Diagnosis

Patient must have **ALL** of the following:

1. Duchenne muscular dystrophy
 - a. Confirmed mutation of the DMD gene that is amenable to exon 51 skipping
 - b. Prescribed by or in consultation with a neurologist specializing in DMD
 - c. Patient will be advised to monitor for hypersensitivity reactions
 - d. Obtain a baseline muscle strength score from **ONE** of the following:
 - i. 6-minute walk test (6MWT)
 - ii. North Star ambulatory assessment (NSAA)
 - iii. Motor Function Measure (MFM)
 - e. **NO** concurrent therapy with another exon skipping therapy for DMD (see Appendix 1)

Prior – Approval *Renewal* Requirements

Age 20 years of age or younger

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Neuromuscular Agents	Original Policy Date:	October 7, 2016
Subject:	Exondys 51	Page:	3 of 6

Diagnosis

Patient must have **ALL** of the following:

1. Duchenne muscular dystrophy
 - a. Patient has had an improvement from baseline in **ONE** of the following:
 - i. 6-minute walk test (6MWT)
 - ii. North Star ambulatory assessment (NSAA)
 - iii. Motor Function Measure (MFM)
 - b. Patient will be advised to monitor for hypersensitivity reactions
 - c. **NO** concurrent therapy with another exon skipping therapy for DMD (see Appendix 1)

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Limits

Duration 24 months

Rationale

Summary

Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Dystrophin levels should be measured at baseline to evaluate pretreatment dystrophin-positive fibers and sometime during therapy to evaluate the effect of Exondys 51 dose (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Exondys 51 while maintaining optimal therapeutic outcomes.

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Neuromuscular Agents	Original Policy Date:	October 7, 2016
Subject:	Exondys 51	Page:	4 of 6

References

1. Exondys 51 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; January 2022.
2. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Ann Neurol.* 2013; 74(5):637-647.
3. Kole R, Krieg AM. Exon skipping therapy for Duchenne muscular dystrophy. *Adv Drug Deliv Rev.* 2015; 87:104-107.

Policy History

Date	Action
October 2016	Addition to PA
December 2016	Annual review
March 2017	Annual editorial review Addition of obtain a baseline dystrophin level and patient has had an improvement from baseline in dystrophin levels Addition of obtain a baseline muscle strength score from one of the following: 6-minute walk distance (6MWD), North Star ambulatory assessment, or Motor Function Measure; and the patient has had an improvement from baseline from one of the scoring tools Addition of prescribed by or in consultation with a neurologist specializing in DMD Addition of the age 20 years of age or younger requirement
July 2017	Annual review
February 2018	Removal of the dystrophin level requirements
June 2018	Annual review and reference update
September 2019	Annual review and reference update
June 2020	Annual review and reference update
December 2020	Annual review and reference update. Per FEP, addition of requirement of no concurrent therapy with another exon skipping therapy for DMD
March 2021	Annual review
June 2021	Annual editorial review. Updated Appendix 1.
March 2022	Annual review and reference update
March 2023	Annual review. Changed policy number to 5.75.014
December 2023	Annual review. Per SME, added requirements to monitor for hypersensitivity reactions
March 2024	Annual review

Keywords

5.75.014

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Neuromuscular Agents	Original Policy Date:	October 7, 2016
Subject:	Exondys 51	Page:	5 of 6

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.

Section: Prescription Drugs **Effective Date:** April 1, 2024
Subsection: Neuromuscular Agents **Original Policy Date:** October 7, 2016
Subject: Exondys 51 **Page:** 6 of 6

Appendix 1 - List of Exon Skipping Therapies for Duchenne Muscular Dystrophy (DMD)

Generic Name	Brand Name
casimersen	Amondys 45
eteplirsen	Exondys 51
golodirsen	Vyondys 53
viltolarsen	Viltepso